✦ LIBER ✦

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Scribed by Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; Andrew Baldassare; Joy Schechtman; Edward Fudman; Michael Kohen; Sheila Gujrathi; Robert G. Trapp; Nadera J. Sweiss; Greg Spaniolo; Wolfgang Dummer; ACTION Study Group

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 623 KB
Volume: 58
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23732

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

The efficacy and safety of rituximab in

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

✍ Paul Emery; Roy Fleischmann; Anna Filipowicz-Sosnowska; Joy Schechtman; Leszek S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB 👁 2 views

A multicenter, double-blind, dose-rangin

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of genant and larsen scores

✍ Yebin Jiang; Harry K. Genant; Iain Watt; Mark Cobby; Barry Bresnihan; Roger Aitc 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 3 views

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views